Abstract:Abstract Background During the early stages of Alzheimer’s disease (AD), patients often suffer from prodromal symptoms such as anxiety, impulsivity, depression, agitation, and sleep disturbances prior to the onset of cognitive impairment. Incidentally, the brainstem noradrenergic locus coeruleus (LC) is the first structure to develop hyperphosphorylated ‘pretangle’ tau pathology in the human brain. Furthermore, norepinephrine (NE) influences several physiological processes such as sleep/wake cycle, arousal, stress, mood, and attention which have been implicated in the prodromal behavioral abnormalities. While clinical studies show significant correlations between LC dysfunction and neuropsychiatric symptoms, a causal relationship between early tau accumulation in the LC and the manifestations of prodromal behaviors remains to be resolved. To explore this, we developed a translationally‐relevant tau mouse model that recapitulates the ‘LC first’ phenomena commonly observed in humans. Method Adult male and female tyrosine hydroxylase (TH)‐Cre mice aged 4 months underwent intra‐LC infusions with a Cre‐dependent adeno‐associated virus (AAV) expressing mCherry, wild‐type (WT) human tau or P301S mutant human tau (n = 3/group). 3 months post‐infusion, mice underwent a panel of behavioral tests to assess sleep latency, locomotor activity, compulsivity, stress‐induced anxiety‐like behavior, association memory deficits, impulsivity, and attentional impairments. Following behavioral tests, brain sections comprising the LC, hippocampus and prefrontal cortex (PFC) were immunostained with TH to assess for LC integrity, AT8 to detect pretangle tau, NE transporter (NET) to evaluate NE fiber intensity in projection regions, and GFAP and IBA1 to identify neuroinflammatory markers. Immunoreactivity (IR) will be calculated as a measure of fluorescence via ImageJ. Result It has been proposed that tau accumulation in the LC may provoke mild to moderate damage in LC neurons, triggering compensatory mechanisms such as LC hyperactivity. It is hypothesized that at 3 months, LC‐specific tau pathology will result in hyperarousal, compulsivity, anxiety‐like behavior, and impulsivity. In tandem, human tau‐expressing mice are expected to display increased TH, reflecting LC hyperactivity, neuroinflammatory markers and reductions in NE fibers in LC‐projecting regions. These findings will be presented in July 2023. Conclusion This research will elucidate the role of LC in governing prodromal symptoms. Further studies will be needed to assess molecular mechanisms underlying tau‐mediated LC dysfunction in early AD.

Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein

Defects in the autophagy lysosomal pathway in a cell model of disease‐associated tau

Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis

Development of an anti-tauopathy mucosal vaccine specifically targeting pathologic conformers

Tau, synapse loss and gliosis progress in an Alzheimer's mouse model after amyloid-β immunotherapy

Passive Immunization With a Novel Monoclonal Anti-PrP Antibody TW1 in an Alzheimer's Mouse Model With Tau Pathology

Amelioration of Tau Related Pathology with a Novel Anti‐prion Protein Monoclonal Antibody in an AD Mouse Model

Vaccines targeting the primary amino acid sequence and conformational epitope of amyloid- had distinct effects on neuropathology and cognitive deficits in EAE/AD mice

Consequences of Pathogenic Tau Expression in Mouse Locus Coeruleus

Tauopathy promotes spinal cord-dependent production of toxic amyloid-beta in transgenic monkeys

Induction and characterisation of Abeta and tau pathology in AppNL-F/NL-F mice following inoculation with Alzheimer's disease brain homogenate

A pentavalent peptide vaccine elicits Aβ and tau antibodies with prophylactic activity in an Alzheimer's disease mouse model

CD4+ effector T cells accelerate Alzheimer's disease in mice

Vaccines targeting the primary amino acid sequence and conformational epitope of Aβ had distinct effects on neuropathology and cognitive deficits in EAE/AD mice.

Recent advances in tau-directed immunotherapy against Alzheimer’s disease: an overview of pre-clinical and clinical development

Humanized Tau Mice with Regionalized Amyloid Exhibit Behavioral Deficits but No Pathological Interaction

Gfp-Mutant Human Tau Transgenic Mice Develop Tauopathy Following Cns Injections Of Alzheimer'S Brain-Derived Pathological Tau Or Synthetic Mutant Human Tau Fibrils

Tau Protein and β-Amyloid Associated with Neurodegeneration in Myelin Oligodendrocyte Glycoprotein-Induced Experimental Autoimmune Encephalomyelitis (EAE), a Mouse Model of Multiple Sclerosis

Early Oligodendrocyte/Myelin Pathology in Alzheimer's Disease Mice Constitutes a Novel Therapeutic Target

Traumatic Brain Injury in Mice Generates Early-Stage Alzheimer’s Disease Related Protein Pathology that Correlates with Neurobehavioral Deficits

Cytosolic antibody receptor TRIM21 is required for effective tau immunotherapy in mouse models